Back to top
more

Apollo Endosurgery, Inc. (APEN)

(Delayed Data from NSDQ)

$3.54 USD

3.54
5,491

-0.28 (-7.33%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.95 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cardiovascular Systems (CSII) Expands Lithotripsy Technology

by Zacks Equity Research

Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.

Medtronic's (MDT) DTM SCS Endurance Therapy Study Data Positive

by Zacks Equity Research

Medtronic's (MDT) DTM SCS endurance therapy offers meaningful clinical benefits by reducing pain, improving quality of life and offering meaningful device longevity for patients.

Down 21.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Apollo Endosurgery, Inc. (APEN)

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why You Should Hold on to Illumina (ILMN) for Now

by Zacks Equity Research

Investors are optimistic about Illumina (ILMN) owing to its strength in international markets and notable strategic partnerships.

Abbott (ABT) Gets FDA Nod for New Cardiac Mapping System

by Zacks Equity Research

Abbott's (ABT) EnSite X EP System with EnSite Omnipolar Technology offers a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise.

Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief

by Zacks Equity Research

Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.

Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist

by Zacks Equity Research

Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.

Quest Diagnostics (DGX) Posts Preliminary Q4 & 2021 Results

by Zacks Equity Research

Quest Diagnostics (DGX) posts preliminary fourth-quarter and full-year results, reflecting an increase in COVID-19 testing services and a steady recovery in the company's base testing volumes.

Integra (IART) Announces Preliminary Q4 & '21 Sales Results

by Zacks Equity Research

Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.

Here's Why You Should Retain Thermo Fisher (TMO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) strong end-market growth and focus on international regions.

Cardiovascular Systems (CSII) Coronary Sales Up Amid COVID Woe

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.

Hologic (HOLX) Up on Preliminary Q1 Organic Sales Growth

by Zacks Equity Research

Hologic's (HOLX) Diagnostics division's preliminary numbers show a strong rebound in the base business.

Here's Why You Should Hold on to Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) given huge market potential in its Invisalign brand and strategic partnerships.

Medtronic (MDT) Gets MHLW Approval for Micra AV Sale in Japan

by Zacks Equity Research

The Micra AV approval is likely to boost Medtronic's (MDT) Cardiac Rhythm Management business while delivering the benefits of leadless pacing in Japan.

Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View

by Zacks Equity Research

Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism.

IDEXX's (IDXX) Low LPD Sales, Rise in Expenses Dampen Growth

by Zacks Equity Research

Distributor purchasing dynamics have an impact on IDEXX's (IDXX) reported sales of CAG products.

Medtronic (MDT) to Buy Affera, Expand in Electrophysiology

by Zacks Equity Research

Affera's full suite of solutions and technologies will complement Medtronic's (MDT) existing atrial and ventricular arrhythmia disease management portfolio.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS), owing to consistent improvement in its consumer-centric digital solutions and raised guidance.

NuVasive (NUVA) Gets FDA Nod for Attrax Putty Expanded Use

by Zacks Equity Research

NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.

Thermo Fisher (TMO) Completes Buyout of PeproTech for $1.85B

by Zacks Equity Research

Thermo Fisher's (TMO) recent acquisition will boost its capabilities to serve in the high-growth cell and gene therapy market.

Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics

by Zacks Equity Research

Illumina's (ILMN) collaboration with SomaLogic will boost the fast-growing high throughput sector of the proteomics market to aid research in biology and disease.

Hologic's (HOLX) GAI Program to Include Aptima SARS-CoV-2 Assay

by Zacks Equity Research

The addition of Aptima SARS-CoV-2 assay to Hologic's (HOLX) Global Access Initiative is likely to improve its accessibility.

Walgreens Boots (WBA) Gains From New Pacts, Faces Margin Woes

by Zacks Equity Research

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margins significantly.

Abbott's (ABT) Proclaim XR SCS Gets FDA Nod for New MRI Label

by Zacks Equity Research

The latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business.

Here's Why You Should Retain Phibro (PAHC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC), given robust performance by its nutritional specialties and vaccine product lines.